Clinical Trials on Blepharospasm, Benign Essential

Total 2347 results

Novartis Pharmaceuticals

Completed

Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg (EXPLOR)

Hypertension

France
LG Life Sciences

Completed

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd
Covance

Completed

Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects

Essential Hypertension
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers

Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers

Essential Hypertension
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension

Hypertension

Korea, Republic of
Kyoto University

Completed

Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

Essential Hypertension

Germany
University of Pavia

Unknown

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

Essential Hypertension

Italy
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
National Center for Complementary and Integrative...

Completed

Hypertension: Prediction of Biofeedback Success

Essential Hypertension

United States
Regional Hospital Holstebro

Completed

Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

Hypertension
IRCCS Policlinico S. Matteo

Completed

Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia (Odyliresin)

Benign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction

Italy
American Medical Systems

Completed

Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)

Benign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
Jordi Gol i Gurina Foundation
Preventive Services and Health Promotion Research Network; Instituto de Salud... and other collaborators

Completed

Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Benign Paroxysmal Positional Vertigo

Benign Positional Paroxysmal Vertigo

Spain
Celltrion

Completed

A Bioequivalence Study of L04TD1 Compared to Administration of L04RD1 in Healthy Volunteers

Healthy

Korea, Republic of
Johns Hopkins Bloomberg School of Public Health
University of Cape Town; Oxford Policy Management

Completed

Kilkari Impact Evaluation

Breast Feeding | Family Planning | Essential Newborn Care | Training of Frontline Health Workers

India
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Australia, New Zealand, Italy
Incyte Corporation

Recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (LIMBER)

Anemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, France, Italy, Japan, Canada, United Kingdom
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, Canada, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
M.D. Anderson Cancer Center

Active, not recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
University of Utah
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Samus Therapeutics, Inc.

Terminated

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
John Mascarenhas
National Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...

Terminated

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Canada, United Kingdom
John Mascarenhas

Terminated

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related Myelofibrosis

United States
Cynosure, Inc.

Completed

755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars

Benign Pigmented and Vascular Lesions and Scars

United States
M.D. Anderson Cancer Center

Completed

Wearable Exercise Trackers in Cancer Rehabilitation

Malignant Neoplasms of Independent (Primary) Multiple Sites | Benign Neoplasms | In Situ Neoplasms

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (FAST)

Essential Thrombocythemia | MPN

France
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm

Hemifacial Spasm | Blepharospasm | Botulinum Toxins, Type A
Second Affiliated Hospital of Guangzhou Medical...
First Affiliated Hospital, Sun Yat-Sen University; West China Hospital; Guangzhou... and other collaborators

Unknown

HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions

Epilepsy | Neuropathy | Blepharospasm | Psychiatric Illness

China
St. Joseph's Healthcare Hamilton

Unknown

Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm

Hemifacial Spasm | Blepharospasm

Canada
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
John Mascarenhas
Massachusetts General Hospital; Montefiore Medical Center

Completed

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Primary Myelofibrosis | Polycythemia Vera | Post-essential Thrombocythemia Myelofibrosis | Chronic Phase Myelofibrosis

United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Ronald Hoffman
Novartis

Unknown

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-Essential Thrombocythemia Related Myelofibrosis

United States
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
Novartis Pharmaceuticals

Withdrawn

Study of Select Combinations in Adults With Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | PMF | Post-Essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals

Completed

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Primary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MF

Taiwan, Japan, Korea, Republic of, China
João Martins Pisco

Completed

Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia

Lower Urinary Tract Symptoms | Prostatic Diseases | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy, Benign | Genital Diseases, Male

Portugal
Children's Hospital Medical Center, Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children (FIRST)

Benign Childhood Epilepsy With Centro-Temporal Spikes

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Spain, United Kingdom, France, Canada
Novartis Pharmaceuticals

Completed

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

Myelofibrosis

Belgium, Colombia, Canada, Italy, Spain, Austria, Germany, Czechia, Thailand, Hungary, Greece, Argentina, Brazil, Israel, Russian Federation, Mexico, Portugal, South Africa, Tunisia, Slovakia, Saudi Arabia, Poland, Algeria, Ireland, Mor...
Hanyang University Seoul Hospital

Completed

Comparison of TLH and LAVH With Over Than 500g

Hysterectomy, Benign Uterine Diseases

Clinical Trials on Blepharospasm, Benign Essential

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations